A new ligand for targeted drug delivery to tumor stromal cells.
Park
Kinam
K
Purdue University, Department of Biomedical Engineering, West Lafayette, Indiana, USA. kpark@purdue.edu
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000378:metabolism; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage* / Q000378:metabolism; D016503:Drug Delivery Systems; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D008024:Ligands; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D020286:Pericytes / Q000378:metabolism; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000378:metabolism; D017154:Stromal Cells / Q000187:drug effects*
D000903:Antibiotics, Antineoplastic; D008024:Ligands; D004317:Doxorubicin; D020797:Receptor, Platelet-Derived Growth Factor beta